Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation

John G. Keilp, PhDab; Sean P. Madden, MSab; Julia E. Marver, BAb; Abigail Frawley, PhDab; Ainsley K. Burke, PhDab; Mohammad M. Herzallah, PhDcd; Mark Gluck, PhD; J. John Mann, MDA; and Michael F. Grunebaum, MDb

ABSTRACT

Objective: Subanesthetic ketamine rapidly reduces depressive symptoms and suicidal ideation in some depressed patients. Its effects on neurocognitive functioning in such individuals with significant suicidal ideation is not well understood, even though certain neurocognitive deficits are associated with suicide behavior beyond clinical symptoms.

Methods: In this study, depressed patients with clinically significant suicidal ideation (n = 78) underwent neuropsychological testing before and 1 day after double-blind treatment with intravenous ketamine (n = 39) or midazolam (n = 39). A subgroup randomized to midazolam whose ideation did not remit after initial infusion received open ketamine and additional neurocognitive testing a day after this treatment. The primary outcome was change in performance on this neurocognitive battery. The study was conducted between November 2012 and January 2017.

Results: Blinded ketamine produced rapid improvement in suicidal ideation and mood in comparison to midazolam, as we had reported previously. Ketamine, relative to midazolam, was also associated with specific improvement in reaction time (Choice RT) and interference processing/cognitive control (computerized Stroop task)—the latter a measure that has been associated with past suicide attempt in depression. In midazolam nonremitters later treated with open ketamine and retested, reaction time and interference processing/cognitive control also improved relative to both of their prior assessments. Neurocognitive improvement, however, was not correlated with changes in depression, suicidal thinking, or general mood.

Conclusions: Overall, ketamine was found to have a positive therapeutic effect on neurocognition 1 day after treatment on at least 1 measure associated with suicidal behavior in the context of depression. Results suggest additional independent therapeutic effects for ketamine in the treatment of depressed patients at risk for suicidal behavior.

Trial Registration: ClinicalTrials.gov identifier: NCT01700829

J Clin Psychiatry 2021;82(6):21m13921


© 2021 Copyright Physicians Postgraduate Press, Inc.

aDepartment of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, New York
bDepartment of Psychiatry, Columbia University College of Physicians and Surgeons, New York, New York
cCenter for Molecular and Behavioral Neuroscience, Rutgers University—Newark, Newark, New Jersey
dPalestinian Neuroscience Initiative, Al-Quds University, Abu Dis, Israel
*Corresponding author: John G. Keilp, PhD, Box 42, NYSPI, 1051 Riverside Dr, New York, NY 10032 (jgk13@cumc.columbia.edu).

Intravenous ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has robust therapeutic effects on both depression and suicidal ideation within hours to days in some depressed patients.1–4 However, its impact on neurocognition, particularly aspects of neurocognition associated with suicidal behavior,5–7 is not well understood.

The effects of ketamine on neurocognition within hours after administration are largely detrimental in healthy volunteers, including adverse effects on attention,8 episodic memory,9 working memory,10,11 semantic processing and priming,12,13 verbal fluency,11 and executive function.11 These effects are dose-dependent.14,15 Deficits appear to resolve within days following ketamine administration in healthy individuals9 and persist only with chronic ketamine use and abuse.15,16

There is evidence in depressed patients, however, that neurocognitive functioning improves within the first few days after infusion, after the resolution of any acute transitory, negative neurocognitive effects and during the period of peak antidepressant effect. Permoda-Osip and colleagues17 observed improvement in performance on the Trail Making Test and a Stroop task 3 days after ketamine infusion in an open study. Murrough and colleagues18 observed general cognitive improvement at 7 days after infusion in a randomized clinical trial comparing ketamine and midazolam for treatment of refractory depression, though improvement was not specific to either drug and uncorrelated with improvement in depressive symptoms. Zheng and colleagues19 observed improvement in speed of processing and verbal learning 1 day after completion of a 12-day course of 6 intravenous infusions of ketamine that was mediated by improvement in depressive symptoms. Effects of ketamine infusion on neurocognition in depressed patients with moderate to severe suicidal ideation, however, are presently unknown.

This study reports neurocognitive results from a randomized trial of ketamine vs midazolam in a sample of depressed patients with clinically significant suicidal ideation. Clinical findings from this study have been reported previously.1 The primary goal was to measure neurocognitive changes from baseline to 24 hours after treatment and to investigate relationships of these changes in neurocognitive performance to changes in depressive symptoms and suicidal thinking. We hypothesized that neurocognitive performance on a standard battery of tests would improve globally with effective treatment, given previous open-label17 and controlled clinical trials,18 and do so within a time period consistent with its clinical effects.
Keilp et al

It is illegal to post this copyrighted PDF on any website.

Clinical Points

- Ketamine has been found to reduce suicidal ideation in at-risk depressed patients, but its effects on neurocognition are not clear.
- Ketamine produced improvement in suicidal thinking, as well as improvement in measures of reaction time and interference processing/cognitive control, in both blinded and open phases of this study.
- Ketamine improved neurocognitive functioning associated with suicidal behavior, beyond its effects on suicidal thinking alone.

Secondly, we examined correlations between neurocognitive performance and measures of clinical response. Previous studies have found an association between baseline cognitive slowing and therapeutic response to ketamine.8,20 We hypothesized that performance on measures of reaction time, processing speed, and timed language fluency would correlate with clinical response. Changes in neurocognitive performance were also examined in relation to clinical response.

Third, a subset of those patients who (a) initially received blinded midazolam, (b) did not show a predefined remission of suicidal thoughts, and (c) chose to receive open-label ketamine (per protocol) were assessed a third time, 1 day after infusion. This assessment was introduced later in the study (on the last 60% of the sample) and was done to determine if neurocognitive functions affected by ketamine during the blinded infusion were similarly affected after open ketamine in those who initially received blinded midazolam and failed to show a clinical response. If these patients did not also show an improvement in neurocognitive performance after midazolam, later administration of ketamine might augment any changes in neurocognitive performance, consistent with the initial effects of the blinded ketamine administration.

METHODS

Subjects

Participants were 78 individuals with major depressive disorder and clinically significant suicidal ideation (out of 80 participants in the full clinical trial), as described in our clinical efficacy paper.1 Two subjects from the full trial sample were dropped for neuropsychological analyses, one who spoke limited English and could not be tested and another who was not cooperative with the testing. Characteristics of participants are presented in Table 1. Registration for the full clinical trial may be found at ClinicalTrials.gov (NCT01700829). The study was approved by the New York State Psychiatric Institute Institutional Review Board, and all participants signed informed consent.

Instruments

Clinical response measures included the 24-item Hamilton Depression Rating Scale (HDRS) and Beck Scale for Suicidal Ideation (SSI).1 The Profile of Mood States (POMS) was administered at the time of each of the neuropsychological assessments.

Neuropsychological measures assessed 10 core functions: reaction time (computerized 4 button Choice Reaction Time task21), psychomotor speed (Wechsler Adult Intelligence Scale—III [WAIS-III] Digit Symbol22 subtest, a timed paper-and-pencil transcription task), attention (computerized Continuous Performance Test [CPT]), Identical Pairs version23; 4-digits fast condition, identifying rapidly presented sequential pairs of 4-digit number strings), cognitive control/interference processing (computerized Stroop Task21,24), immediate memory (Buschke Selective Reminding Test [SRT], Total Immediate Recall25 for a 12-item word list, over 12 trials), delayed memory (Buschke SRT, Delayed Recall25 of word list at 30 minutes), working memory/reasoning speed (computerized A Not B Timed Reasoning Task,21 rapidly solving syllogisms based on letter order), letter (phonemic) fluency (Controlled Oral Word Association Test, Letters,26 generating words beginning with specific letters with a minute), category (semantic) fluency (Controlled Oral Word Association Test, Animal naming,26 generating as many animals as possible within 1 minute), and inhibitory control (computerized Go–No Go Task,21 a computerized bimodal matching [auditory tone and location on screen], target identification task). The battery was designed to assess processing speed, attention, memory, concentration, language skills, and impulse control—all of which may be affected by depression and/or suicide risk5,6 before and after treatment. Primary outcome measures for each task are listed in Table 2. Alternate forms of Digit Symbol, CPT, Buschke SRT, and Letter Fluency were used in repeated assessments to reduce practice effects. Choice Reaction Time and Go–No Go measures used randomized and counterbalanced item order within each administration. Scores were converted to age, sex, and/or education adjusted z scores based on published normative data or archived normative data from our laboratory,21 consistent with prior publications.5,6,27 Conversion of performance measures to a common z score metric allowed for the use of all neuropsychological measures in an omnibus analysis and for direct comparison of changes across tasks in z-score units.

Procedures

Participants were recruited by advertisement and clinician referral. All met criteria for current DSM-5 major depressive disorder, with a minimum 17-item HDRS score ≥ 16 and SSI score ≥ 4—a clinically significant cutoff. All participants were admitted to an inpatient research unit at the New York State Psychiatric Institute for acute treatment and discharged when judged not an imminent safety risk. Exclusion criteria were described previously.1 Current psychiatric medications were continued at stable doses with the exception of benzodiazepines, which were discontinued at least 24 hours prior to infusion and neuropsychological testing.

Participants, raters, and physicians were blind to randomization to 0.5 mg/kg racemic ketamine or 0.02 mg/
kg midazolam IV infusion. Blood pressure, pulse oxygenation saturation, and heart and respiratory rates were monitored continuously during the 40-minute infusion by a study psychiatrist.

Baseline neurocognitive assessment was completed 1–3 days prior to blinded infusion (referred to below as day minus-1), and participants were reassessed approximately 24 hours after this infusion (day 1; infusion day designated as day 0).

To provide all patients a chance to receive ketamine, nonremitters at day 1 after blinded infusion (remission defined as a decline in SSI of at least 50% below baseline and below the eligibility cutoff of 4) had their blind broken. Those who had received midazolam were offered an open ketamine infusion the next day. In the full clinical trial, a total of 35 patients who had not responded to midazolam received this open ketamine infusion. Because the neuropsychological assessment after open ketamine was not begun until approximately 40% of the sample had been recruited, 22 subjects were available for this third neuropsychological assessment; 21 completed the assessment.

The study was conducted between November 2012 and January 2017.

Statistical Analyses
 Baseline clinical and demographic data were compared between patients randomized to midazolam or ketamine via t test for continuous variables or χ² for categorical variables.

Treatment-related changes in depression severity (HDRS), suicidal ideation (SSI), and mood (POMS) were compared in repeated measures analyses of variance.

The primary analysis of neurocognitive performance was an omnibus comparison of performance across the full neuropsychological battery, in the two drug assignment groups, from baseline (day minus-1) to the day after the blinded infusion (day 1). Analysis was undertaken via a general linear model, with main effects for assessment point (baseline vs day 1), drug assignment (midazolam vs ketamine), and test (10 levels, corresponding to the primary outcome measure for each test) and all interactions. Following this omnibus analysis, significant main effects and interactions were examined in univariate comparisons of individual tests, across assessment point and drug assignment. Analyses were performed in a hierarchical fashion, with individual test comparisons uncorrected for multiple comparisons if omnibus analysis including all test measures was significant.

Correlations were then computed between (a) baseline neuropsychological test performance and change in primary clinical outcome measures, including HDRS, SSI, and POMS total score, and (b) change in neuropsychological test performance and the change in these primary clinical outcome measures.

For midazolam nonremitters who received open ketamine and completed the third neuropsychological assessment, performance was compared across 3 time points (day minus-1 baseline, day 1 post–blinded infusion, and day 3 post–open ketamine). A significant omnibus effect for assessment point (3 levels) or an assessment point × test interaction led to follow-up univariate comparisons of individual tests. A significant univariate effect for assessment point in univariate comparisons was then followed by pairwise post hoc comparison of each assessment day. The pairwise difference in performance between the post–blinded infusion day (day 1) and the post–open ketamine day (day 3) was the critical planned pairwise comparison, as it reflected change after open ketamine accounting for any practice effect after the blinded midazolam infusion.

RESULTS
Baseline Characteristics
 Treatment groups were comparable at baseline in demographics, clinical characteristics, and concomitant medications (Table 1). Both had an average estimated intelligence in the superior range (≥ 90th percentile of population).

Clinical Changes After Blinded Infusion
 For those receiving neurocognitive assessment, HDRS score improved in both treatment groups (assessment point effect, F₁,₇₆ = 63.27, P < .001) but did not significantly favor ketamine (assessment point × drug interaction, F₁,₇₆ = 2.91, P = .092; see Table 2). SSI improved in both groups (F₁,₇₆ = 63.10, P < .001), but to a greater degree with ketamine compared to midazolam (F₁,₇₆ = 7.31, P = .008). POMS scores obtained at the time of neuropsychological testing also improved in both groups (F₁,₇₄ = 86.04, P < .001), but more so with ketamine (F₁,₇₄ = 9.91, P = .002).

Neurocognitive Changes After Blinded Infusion
 Omnibus analysis of all neuropsychological test scores revealed a significant effect of assessment point (F₁,₇₆ = 15.83, P < .001), a marginal assessment point × drug interaction (F₁,₇₆ = 3.58, P = .062), and a significant assessment point × drug × test interaction (F₁₀,₆₈₄ = 2.75, P = .004).

Performance on the battery overall improved regardless of drug assignment on day 1 (Figure 1). While favoring ketamine relative to midazolam at a trend level (P = .062), overall change was not uniform across the entire battery.

There was a significant interaction of assessment point × drug × test due to greater relative improvement with ketamine compared to midazolam on 3 tasks: Choice RT (assessment point × drug interaction, F₁,₇₅ = 4.21, P = .044), Stroop Interference (F₁,₇₆ = 4.43, P = .039), and Buschke Delayed Recall (F₁,₇₆ = 5.91, P = .017). Choice RT and Stroop Interference improved after ketamine (t₃₈ = 3.85, P < .001 for Choice RT; t₃₈ = 2.85, P = .007 for Stroop), with no change after midazolam (t₃₈ = 0.82, P = .419; t₃₈ = 0.28, P = .780). However, for Buschke Delayed Recall, improvement after ketamine was nonsignificant (t₃₈ = 1.66, P = .106), with a trend toward worsening after midazolam (t₃₈ = 1.80, P = .081).

Including a covariate for baseline medication status (yes/no) did not alter the significant assessment point × drug × test interaction (F₁₀,₆₇₅ = 2.80, P = .003).
### Table 1. Demographic and Clinical Characteristics

<table>
<thead>
<tr>
<th>Variable</th>
<th>Midazolam treated (n = 39)</th>
<th>Ketamine treated (n = 39)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variable</td>
<td>Mean (SD)</td>
<td>Mean (SD)</td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>39.6 (13.0)</td>
<td>37.2 (12.9)</td>
<td>.429</td>
</tr>
<tr>
<td>Education, y</td>
<td>15.7 (2.4)</td>
<td>16.1 (1.9)</td>
<td>.437</td>
</tr>
<tr>
<td>WAIS-III Vocabulary subtest</td>
<td>14.4 (2.9)</td>
<td>14.6 (2.7)</td>
<td>.687</td>
</tr>
<tr>
<td>BMI</td>
<td>29.1 (8.6)</td>
<td>26.6 (5.6)</td>
<td>.135</td>
</tr>
<tr>
<td>Age at onset of first episode of MDD, y</td>
<td>17.7 (10.3)</td>
<td>17.6 (9.9)</td>
<td>.969</td>
</tr>
<tr>
<td>Number of episodes of MDD</td>
<td>11.3 (18.3)</td>
<td>17.2 (20.8)</td>
<td>.178</td>
</tr>
<tr>
<td>Duration of current episode of MDD, wk</td>
<td>[median = 3]</td>
<td>[median = 5]</td>
<td></td>
</tr>
<tr>
<td>Rating scale scores (baseline)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDRS-24</td>
<td>30.0 (5.9)</td>
<td>29.1 (5.9)</td>
<td>.949</td>
</tr>
<tr>
<td>SSI</td>
<td>15.4 (6.7)</td>
<td>14.4 (6.4)</td>
<td>.503</td>
</tr>
<tr>
<td>POMS</td>
<td>110.6 (38.5)</td>
<td>107.3 (33.0)</td>
<td>.687</td>
</tr>
<tr>
<td>Sex, female</td>
<td>25 (64.1)</td>
<td>22 (56.4)</td>
<td>.488</td>
</tr>
<tr>
<td>Native language</td>
<td>English 39 (100.0)</td>
<td>37 (94.9)</td>
<td>.152</td>
</tr>
<tr>
<td>Race</td>
<td>European-American 37 (97.4)</td>
<td>34 (87.2)</td>
<td>.128</td>
</tr>
<tr>
<td>Black or African-American 1 (2.6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>0 (0.0)</td>
<td>4 (10.3)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity: Hispanic</td>
<td>2 (5.1)</td>
<td>0 (0.0)</td>
<td>.308</td>
</tr>
<tr>
<td>At least 1 prior hospitalization</td>
<td>28 (71.8)</td>
<td>26 (66.7)</td>
<td>.624</td>
</tr>
<tr>
<td>Concurrent medications</td>
<td>None 12 (30.8)</td>
<td>12 (30.8)</td>
<td>…</td>
</tr>
<tr>
<td>Any medication</td>
<td>27 (69.2)</td>
<td>27 (69.2)</td>
<td>1.000</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>22 (56.4)</td>
<td>20 (51.3)</td>
<td>.650</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>9 (23.1)</td>
<td>10 (25.6)</td>
<td>.792</td>
</tr>
<tr>
<td>Antipsychotics</td>
<td>5 (12.8)</td>
<td>8 (20.5)</td>
<td>.362</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>11 (28.2)</td>
<td>15 (38.5)</td>
<td>.337</td>
</tr>
<tr>
<td>Lithium</td>
<td>1 (2.6)</td>
<td>1 (2.6)</td>
<td>1.000</td>
</tr>
<tr>
<td>Suicide attempt history—past suicide attempt</td>
<td>21 (53.8)</td>
<td>17 (43.6)</td>
<td>.365</td>
</tr>
<tr>
<td>Psychopathology</td>
<td>Any personality disorder</td>
<td>12 (34.3)</td>
<td>.492</td>
</tr>
<tr>
<td>Past history of substance abuse</td>
<td>8 (20.5)</td>
<td>7 (17.9)</td>
<td>.774</td>
</tr>
</tbody>
</table>

Abbreviations: BMI = body mass index, HDRS-24 = Hamilton Depression Rating Scale 24-item, MDD = major depressive disorder, POMS = Profile of Mood States, SSI = Scale for Suicide Ideation, WAIS-III = Wechsler Adult Intelligence Scale—III.

### Table 2. Clinical Severity and Neurocognitive Performance Across Treatment Conditions and Assessment Time Points

<table>
<thead>
<tr>
<th>Test7</th>
<th>Midazolam treated</th>
<th>Ketamine treated</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDRS-24</td>
<td>Midazolam baseline</td>
<td>Midazolam post-infusion</td>
<td>Ketamine baseline</td>
</tr>
<tr>
<td>HDRS-24</td>
<td>30.0 (5.9)</td>
<td>29.1 (5.9)</td>
<td>19.5 (9.4)</td>
</tr>
<tr>
<td>SSI</td>
<td>15.4 (6.7)</td>
<td>14.4 (6.4)</td>
<td>6.1 (5.6)</td>
</tr>
<tr>
<td>POMS</td>
<td>110.6 (38.5)</td>
<td>107.3 (33.0)</td>
<td>33.0</td>
</tr>
<tr>
<td>Choice RT</td>
<td>−0.21 (1.16)</td>
<td>−0.09 (1.65)</td>
<td>−0.73 (1.50)</td>
</tr>
<tr>
<td>Digit Symbol</td>
<td>−0.63 (1.05)</td>
<td>−0.47 (1.22)</td>
<td>−0.33 (1.01)</td>
</tr>
<tr>
<td>CPT d7</td>
<td>−0.15 (1.10)</td>
<td>0.19 (1.04)</td>
<td>0.03 (1.13)</td>
</tr>
<tr>
<td>Stroop Interference</td>
<td>−0.23 (1.03)</td>
<td>−0.27 (1.04)</td>
<td>−0.31 (1.09)</td>
</tr>
<tr>
<td>Buschke SRT Immediate</td>
<td>−0.16 (1.41)</td>
<td>−0.16 (1.50)</td>
<td>−0.02 (1.28)</td>
</tr>
<tr>
<td>Buschke SRT Delayed</td>
<td>0.21 (1.94)</td>
<td>−0.40 (2.27)</td>
<td>0.02 (1.61)</td>
</tr>
<tr>
<td>A Not B RT</td>
<td>−0.35 (1.35)</td>
<td>0.24 (1.16)</td>
<td>−0.33 (1.10)</td>
</tr>
<tr>
<td>Letter Fluency</td>
<td>0.31 (1.16)</td>
<td>0.50 (1.14)</td>
<td>0.01 (1.09)</td>
</tr>
<tr>
<td>Category Fluency</td>
<td>0.04 (0.94)</td>
<td>0.08 (1.14)</td>
<td>−0.12 (1.02)</td>
</tr>
<tr>
<td>Go–No Go Commission Error</td>
<td>−0.42 (0.87)</td>
<td>−0.11 (1.11)</td>
<td>−0.23 (1.09)</td>
</tr>
</tbody>
</table>

*HDRS-24, SSI, and POMS values reflect mean (SD) total scores. All neurocognitive test scores are z-scores adjusted for age, sex, and/or education.

*P < .05 for time × drug interaction.

Abbreviations: Buschke SRT = Buschke Selective Reminding Test, CPT = Continuous Performance Test, HDRS-24 = Hamilton Depression Rating Scale 24-item, POMS = Profile of Mood States, RT = reaction time.
Correlations With Clinical Response

Baseline Buschke SRT immediate performance correlated with the decline in HDRS score \( r = -0.39, P = .016 \), but was only 1 of 30 correlations to fall below a nominal significance level of \( P < .05 \).

We did not find associations between slower baseline processing speed and change in the HDRS (Choice RT, \( r = 0.09, P = .579 \); Digit Symbol, \( r = 0.10, P = .559 \); Letter Fluency, \( r = -0.07, P = .665 \); Category Fluency, \( r = -0.05, P = .766 \)), the SSI (respectively, \( r = 0.10, P = .564 \); \( r = 0.06, P = .725 \); \( r = 0.02, P = .915 \); \( r = -0.07, P = .690 \)), or the POMS (respectively, \( r = 0.08, P = .476 \); \( r = 0.05, P = .786 \); \( r = 0.05, P = .786 \); \( r = -0.08, P = .651 \)).

Change in neuropsychological performance after the blinded ketamine infusion (ketamine group only) was not significantly correlated with change on any clinical severity measure.

Clinical Changes After Open Ketamine

The subsample of midazolam nonremitters who received open ketamine and neuropsychological testing \( n = 21 \) improved clinically on the HDRS \( F_{2,40} = 19.94, P < .001 \),
Neurocognitive Changes After Open Ketamine

In the omnibus comparison of performance across all tests and all assessment days in this subgroup, there was overall improvement across the 3 assessment points ($F_{2,40} = 18.40, P < .001$; see Figure 2). Average z-score across all tests by day 3 (+0.30 ± 0.63) was significantly better than at either baseline ($-0.22 ± 0.76, P < .001$) or day 1 ($-0.04 ± 0.80, P < .001$).

Day 3 (post–open ketamine) performance was improved relative to both day 1 and baseline on Choice RT ($F_{2,40} = 10.86, P < .001$), WAIS-III Digit Symbol ($F_{2,40} = 10.18, P < .001$), Stroop Interference ($F_{2,40} = 5.40, P = .008$), and both Letter ($F_{2,40} = 7.50, P = .002$) and Category Fluency ($F_{2,40} = 10.13, P < .001$). Performance on either the Buschke SRT Immediate or Delayed did not improve after open ketamine.

After open ketamine, improvements in neuropsychological test performance again were not correlated with clinical improvement.

DISCUSSION

In the context of a modest general improvement of cognition 24 hours after infusion in both treated groups, Choice Reaction Time and Stroop Interference, measures of response time and interference processing/cognitive control, improved selectively after subanesthetic ketamine in depressed patients with clinically significant suicidal ideation. Changes in these test scores were not correlated with one another ($r = -0.06, P = .72$), making it unlikely that improvement in cognitive control was simply a function of faster response times. These same tests also improved significantly within the same timeframe after open ketamine treatment in the subgroup of nonremitters to blinded midazolam, suggesting a ketamine-specific effect. Improvement of approximately a third of a standard deviation across all tests during this open phase is unlikely due to practice effects.

Relative drug-related changes favoring ketamine were observed on delayed memory performance after blinded infusion but appeared to reflect a decline in performance after midazolam rather than improvement after ketamine.

Neurocognitive performance generally improved 1 day after blinded infusion with either ketamine or midazolam, suggesting that most acute negative effects of these drugs had dissipated by this time—the exception being the marginal decline in memory retention 24 hours after midazolam, consistent with known acute benzodiazepine effects on memory28,29 despite the relatively short half-life of midazolam.30

Consistent with other research, neurocognitive changes observed in our study were not associated with clinical changes after a single infusion,19 although such correlations were found in at least 1 study that assessed neurocognition after multiple infusions and more extensive clinical change.19

The lack of association between clinical change and ketamine’s effects on response time and interference processing/cognitive control suggests a potential additive feature of ketamine’s antisuicidal properties beyond its...
effects on suicidal ideation itself. Measures of interference processing/attentional control, assessed here via a computerized Stroop task, have been associated with past suicide attempt in our[5,6] and others’ previous research[7]—though not with suicidal ideation[5,6] or even depression severity as assessed on standard rating scales.31 Our finding of improvement in Stroop task performance after both blinded and open ketamine infusion is consistent with at least 1 other report assessing Stroop performance.17 To the degree that such neuropsychological performance deficits constitute an independent risk factor for suicide attempt, improvement after ketamine may reduce suicide risk in ways other than reduction in ideation and depressive symptoms alone. It is unclear whether these neurocognitive effects might dissipate at the same rate as other global antidepressant effects.

The mechanisms underlying any specific neurocognitive effects are unclear. Li and colleagues[22] had demonstrated a link between subanesthetic ketamine administration and activation of the mTOR pathway, leading to rapid synapse formation and signaling in medial prefrontal cortex in rodents, suggesting the possibility of a link to effects on neurocognitive tasks sensitive to prefrontal function, though other animal studies suggest this effect may occur in other brain regions as well, such as hippocampus.33,34 In human studies with substance abusing populations, ketamine reduces cravings for both cocaine35 and alcohol36 in clinical laboratory paradigms, an effect attributed in part to improved decision making. The role that improved cognitive control plays in such resistance to urges and cravings is unclear, though psychological theories of self-regulation place central importance on this cognitive capability for managing urges and cravings.37–39

We did not observe an association between baseline slowed processing speed and reduction in depression severity, overall mood disturbance, or suicidal ideation—as reported elsewhere.18,20 This may be due in part to the high estimated intelligence of the sample, which we have previously found to attenuate patient/non-patient differences in processing speed.40 Recruitment of such a sample may have resulted from a reliance on online advertising of the study, rather than direct referral from clinicians.

The lack of an untreated or placebo-treated sample limited our ability to determine the precise degree to which neuropsychological changes reflect practice effects rather than treatment effects. However, in a prior study27 comparing neuropsychological performance after 6 weeks of treatment with bupropion or paroxetine, both treatment groups exhibited clinical improvement but no change in Stroop Interference using the same task employed in this study. Similarly, internal laboratory data in a sample of healthy volunteers (described previously21; data available from the corresponding author on request) revealed no practice effect on the interference measure of this task when repeated after 1 week. The prevalence of concurrent medications may have attenuated some clinical and neuropsychological effects, though no differences were observed in neurocognitive change between those who were and were not taking other medications.

All conclusions drawn here are based on the effects of a single treatment, but at a time when repeated treatment is becoming more common,41 particularly with approval of an intranasal form of ketamine designed to be administered as a maintenance treatment.42 Overall, in this sample of depressed adults with suicidal ideation, neurocognitive improvement at 24 hours after a single, subanesthetic ketamine infusion appeared specific to response time and interference processing/attention control tasks. These improvements were independent of reductions in depression severity or suicidal ideation, suggesting that ketamine-related therapeutic effects on neurocognition may be orthogonal to ketamine's effects on mood symptoms. Neuropsychological risks of long-term, repeated therapeutic ketamine treatment are unknown but warrant further study given that heavy, chronic use, as in addiction, is associated with neurocognitive impairment.15,16 with some impairment persisting even when use is discontinued.43

REFERENCES

10. Honey RA, Turner DC, Honey GD, et al. Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of...


For reprints or permissions, contact permissions@psychiatrist.com. © 2021 Copyright Physicians Postgraduate Press, Inc.